Your browser doesn't support javascript.
loading
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Marusiak, Anna A; Stephenson, Natalie L; Baik, Hayeon; Trotter, Eleanor W; Li, Yaoyong; Blyth, Karen; Mason, Susan; Chapman, Phil; Puto, Lorena A; Read, Jon A; Brassington, Claire; Pollard, Hannah K; Phillips, Chris; Green, Isabelle; Overman, Ross; Collier, Matthew; Testoni, Ewelina; Miller, Crispin J; Hunter, Tony; Sansom, Owen J; Brognard, John.
Afiliación
  • Marusiak AA; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Stephenson NL; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Baik H; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Trotter EW; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Li Y; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Blyth K; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Mason S; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Chapman P; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Puto LA; Salk Institute for Biological Studies, La Jolla, California.
  • Read JA; Discovery Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Brassington C; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Pollard HK; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Phillips C; Discovery Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Green I; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Overman R; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Collier M; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Testoni E; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Miller CJ; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. RNA Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Hunter T; Salk Institute for Biological Studies, La Jolla, California.
  • Sansom OJ; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Brognard J; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. John.Brognard@cruk.manchester.ac.uk.
Cancer Res ; 76(3): 724-35, 2016 Feb 01.
Article en En | MEDLINE | ID: mdl-26637668
MLK4 is a member of the mixed-lineage family of kinases that regulate the JNK, p38, and ERK kinase signaling pathways. MLK4 mutations have been identified in various human cancers, including frequently in colorectal cancer, where their function and pathobiological importance have been uncertain. In this study, we assessed the functional consequences of MLK4 mutations in colon tumorigenesis. Biochemical data indicated that a majority of MLK4 mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects. In seeking to understand the abrogated activity of these mutants, we elucidated a new MLK4 catalytic domain structure. To determine whether MLK4 is required to maintain tumorigenic phenotypes, we reconstituted its signaling axis in colon cancer cells harboring MLK4-inactivating mutations. We found that restoring MLK4 activity reduced cell viability, proliferation, and colony formation in vitro and delayed tumor growth in vivo. Mechanistic investigations established that restoring the function of MLK4 selectively induced the JNK pathway and its downstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B. Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Colon / Quinasas Quinasa Quinasa PAM / Sistema de Señalización de MAP Quinasas Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Colon / Quinasas Quinasa Quinasa PAM / Sistema de Señalización de MAP Quinasas Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido